99mTc-gentamicin: Chemical and biological evaluation

Ozker, K; Urgancioglu, I

doi:10.1007/bf00253169

Cited by 7 publications

(6 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[ 99m Tc]streptomycin was only evaluated in turpentine-infected mice where it was shown that uptake in the inflamed lesion was 2fold increased [88]. [ 99m Tc]gentamicin was only evaluated as renal functional imaging agent [89].…”

Section: Radiolabeled Aminoglycosidesmentioning

confidence: 99%

“…(e.g., 68 Ga and 64 Cu for PET-diagnosis and 90 Y for radionuclide therapy). Siderophores have been applied as a bifunctional chelator to complex 89 Zr instead of desferrioxamine.…”

Section: Siderophoresmentioning

confidence: 99%

“…The availability of GMP-compliant generators would make 68 Ga labeled compounds a desirable mode of chelating compounds to produce useful tracers in the management of DFIs [135]. Radioisotopes with longer half-lives such 64 Cu and 89 Zr may offer a good alternative for labeling of peptides which are currently labeled with 68 Ga. These relatively longer acting radioisotopes will make delayed imaging, which is a requirement in infection imaging, possible.…”

Section: Future Perspectivesmentioning

confidence: 99%

“…64 Cu is likely to be more available as a simpler method of production has recently become available [136]. The long half-life of 78 hours of 89 Zr also makes it an attractive label for large proteins such as antibodies, however, the benefit must be weighed against the radiation burden the patient is exposed to with a long-lived radioisotope [137]. The possibility of hybrid imaging would also allow the application of these potential new tracers in PET/MRI or even PET/CT when MRI cannot be performed to allow pre-and intra-operative assessment of DFIs requiring surgery.…”

Section: Future Perspectivesmentioning

confidence: 99%

See 3 more Smart Citations

New Imaging Tracers for the Infected Diabetic Foot (Nuclear and Optical Imaging)

Ankrah

Klein

Elsinga

2018

CPD

View full text Add to dashboard Cite

Diabetic Foot Infections (DFIs) are associated with increased morbidity, an economic burden on patients, their families and healthcare systems and increased mortality. Early diagnosis with prompt, appropriate and adequate treatment of the infected diabetic foot is crucial. The determination of DFIs, however, may be quite perplexing and invasive. Imaging is useful in the evaluation of certain cases of DFIs, especially in suspected instances with no overt clinical features, or in the diagnosis of osteomyelitis. Nuclear medicine imaging is currently used in the evaluation of DFIs; however, like all the imaging techniques now available, it has its limitations. Several radiopharmaceuticals presently available play useful roles in the management of DFIs, while new ones are being evaluated. Optical imaging techniques have recently demonstrated promising results in the evaluation of many infections including DFIs. Using the same molecule, a tracer can be labeled with a radioisotope or an optical imaging dye. This enables infections to be evaluated both pre- and intra-operatively when surgery is required in their management. In some cases, tracers have been simultaneously labeled with both a radioisotope and an optical imaging dye to produce a hybrid tracer. These new tracers potentially provide powerful and new opportunities in the management of DFIs. In this review, we briefly examine tracers that have been used in the evaluation of the infected diabetic foot. We then explore the potential of new imaging tracers currently under development for infection that may be useful in the management of DFIs.

show abstract

Section: Radiolabeled Aminoglycosidesmentioning

confidence: 99%

“…(e.g., 68 Ga and 64 Cu for PET-diagnosis and 90 Y for radionuclide therapy). Siderophores have been applied as a bifunctional chelator to complex 89 Zr instead of desferrioxamine.…”

Section: Siderophoresmentioning

confidence: 99%

Section: Future Perspectivesmentioning

confidence: 99%

Section: Future Perspectivesmentioning

confidence: 99%

See 2 more Smart Citations

New Imaging Tracers for the Infected Diabetic Foot (Nuclear and Optical Imaging)

Ankrah

Klein

Elsinga

2018

CPD

View full text Add to dashboard Cite

show abstract

“…A synthetic peptide sequence derived from the variable domains of a tumor associated antibody is usually sufficient for antigen binding onto some tumors [197]. Their plasma clearance as well as accumulation in the target tissue is more rapid compared to antibodies resulting in lower myelotoxicity.…”

Section: Peptidesmentioning

confidence: 99%

Preface

Ercan¹,

Çağlar²

2000

CPD

View full text Add to dashboard Cite

A variety of radiopharmaceuticals have been introduced for the internal therapy of malignant and inflammatory lesions in nuclear medicine. In order to destroy the diseased tissues radionuclides with high linear energy transfer (LET) such as beta, alpha, Auger or low energy conversion electron emitters are needed. The range of beta particles is in mm's so they are effective for large tumors. The range of alpha particles is short, only a few cell diameters. Thus, they are effective in treating circulating malignant cells and micrometastases. The range of Auger and conversion electrons is <0.1 micro m. They are very effective in cell killing when they are carried across cell membrane into the nucleus to damage DNA. Appropriate ions, molecules and particles are labelled with such radionuclides and used as radiopharmaceuticals in many different applications. For an effective dose to be delivered high target to non target ratios must be attained. Monoclonal antibodies to specific antigens expressed on tumor cells have been developed to increase the uptake by malignant tissues by specific accumulation. Radiolabelled peptides such as somatostatin, small molecules such as metaiodo-benzylguanidine (MIBG) and many different nano-and micro-particles have been investigated. The effectiveness of therapy can be increased by direct locoregional administration of the radiopharmaceutical. This way the radiation effects are confined locally and the normal tissues are spared from radiation effects. In this review article selection criteria and characteristics of radionuclides and carrier ions, molecules and particles for various therapeutic applications will be discussed, including mainly the recent developments.

show abstract